Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences
Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (Nasdaq: CSTL). Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies. Its TissueCypher® Barrett's Esophagus Assay is the first precision medicine. – See more at: https://www.prnewswire.co Read More
Cernostics CEO on the opportunities ahead with Castle’s acquisition
Cernostics CEO Michael Hoerres said his biotech company's presence will not just remain but grow in Pittsburgh with the pending acquisition by Castle Biosciences Inc. On Wednesday, Castle Biosciences Inc. announced it would acquire Cernostics for $30 million with the potential for $50 million more in cash and stock with the achievement of certain milestones. – See more at: https://www.bizjournals. Read More
Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus
Objective risk assessment guides surveillance and treatment Patients with Barrett’s esophagus (BE) face a low but consequential risk of progression to esophageal adenocarcinoma, for which treatments are limited. Gastroenterologists need reliable methods to assess progression risk in BE patients .... Read More
Improved Testing for Barrett's Esophagus
This is a companion article to the CLP feature, "The New Path Forward." Over the past few decades, there has been a dramatic increase in the incidence of esophageal cancer (EC), a highly lethal disease known to have a 5-year survival rate of just 17%. Data from the National Cancer Institute indicate that EC has increased at a pace greater than any other type of cancer, growing by 500% since the 19 Read More
NewCo on the Go: Cernostics aims to help GIs manage Barrett’s patients
Gastroenterologists are usually quick to admit they do not have a good way to manage patients with Barrett's esophagus. They know Barrett's is a precursor to esophageal cancer, but they don't have a great way of predicting which Barrett's patients are likely to progress to esophageal cancer and which patients probably won't develop the cancer. Cernostics (Pittsburgh), a young company taking Read More
Cernostics gets $100,000 in funding
By Kris B. Mamula, Pittsburgh Business Times Uptown Pittsburgh-based Cernostics Inc. will receive $100,000 in funding to advance development of its lead product, which will help diagnose patients at risk for esophageal cancer. The Ben Franklin Technology Partners of Northeastern Pennsylvania provided the funds. Cernostics is collaborating with health care organizations worldwide to b Read More
Pittsburgh life sciences company developing diagnostic test for esophageal cancer
By Deb Smit, NEXTpittsburgh Pittsburgh life sciences company Cernostics is on the forefront of a diagnostic test for the early detection of esophageal cancer. Company researchers have been working under the radar since 2010 to develop a potentially life-saving platform that will help gastroenterologists identify patients who are at risk of developing cancer of the esophagus. G Read More
Cernostics receives 3 patents
By Kris B. Mamula, Pittsburgh Business Times Cancer diagnostics company Cernostics announced Tuesday it had received two patents in the United States and a third patent in Japan. The patents pertain to different aspects of the Uptown Pittsburgh company's TissueCypher™ technology platform. "These patents are an important part of our intellectual property strategy and pro Read More
Diagnostic developer with faster, more accurate esophageal cancer test nets follow-on funding
By Stephanie Baum, MedCity News Esophageal cancer is one of the fastest growing cancers in western countries and has one of the highest mortality rates among cancers. About 17,990 new cases are diagnosed in the United States each year, according to data from the American Cancer Society. More than 15,000 people die from esophageal cancer annually. Medical device company Cernostics is Read More
Cernostics taps patient registry
By Kris B. Mamula, Pittsburgh Business Times Cancer diagnostics company Cernostics announced collaboration with the Academic Medical Center in The Netherlands, which will give the Oakland company access to one of the world's biggest Barrett's Esophagus patient registries in the world. Barrett's Esophagus is a precursor to esophageal cancer, which has a five-year survival rate of just Read More
Cernostics Collaborates with Academic Medical Center in The Netherlands
Posted on 08, Jan 2014 by Jonathan Kersting Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that it is collaborating with the Academic Medical Center in The Netherlands (AMC). As part of the collaboration, AMC will be providing Cernostics with access to one of the largest Barrett's Esop Read More
Cernostics, Dutch Medical Center Collaborate on Barrett’s Esophagus-related Cancer
NEW YORK (GenomeWeb News) – Cernostics said on Tuesday it is collaborating with the Academic Medical Center in the Netherlands to complete validation studies of the company's test for cancer in patients with Barrett's Esophagus. AMC will provide Cernostics access to its Barrett's Esophagus patient registry, which Cernostics will use to complete studies of its TissueCypher:Barrett's. Under t Read More
Cancer Dx Firm Cernostics Raises $1.4M
NEW YORK (GenomeWeb News) – Cancer diagnostics and prognostics firm Cernostics recently announced it raised $1.4 million in a Series B financing round. The funds will be used to further develop and commercialize the Pittsburgh-based company's lead product called TissueCypher: Barrett's. Its technology, Cernostics said, quantifies whole slide digital images, providing more information and ac Read More
Cernostics raises $1.4M in Series B funding
By Paul J Gough, Digital Producer A Pittsburgh-based life sciences company has raised $1.4 million in Series B funding for its work on a next-generation cancer diagnostic tool. Cernostics said Tuesday the funding included original investors Pittsburgh Life Sciences Greenhouse, Geisinger Health System and Novitas Capital. The $1.4 million in Series B funding announced Tuesday will go Read More
Cancer Diagnostics Company Cernostics Raises $1.4M Series B
Cernostics Inc., which is developing cancer diagnostics, has raised $1.4 million in Series B funding as it advances a test for esophageal cancer. Original investors participating in the round include Geisinger Health System, Novitas Capital and Pittsburgh Life Sciences Greenhouse. Cernostics has now raised more than $6 million including grants and investments, it said. Valuation wasn't dis Read More
Cancer MDx Firm Cernostics Seeks to Raise $500K
NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm Cernostics has filed a document with the US Securities and Exchange Commission saying it plans to raise $500,000. The Pittsburgh-based company, which also has offices in Danville, Penn., did not respond to a request for comment, but in its Form D, it said that it raised $125,000 toward its targeted amount. Securities offered as p Read More
Cernostics Receives $100K Loan from Ben Franklin Technology Partners of Northeastern Pennsylvania
Cernostics, Inc., a Danville, PA-based life science company developing new molecular diagnostic tests, has received a $100k loan from the Ben Franklin Technology Partners of Northeastern Pennsylvania. Led by Mike Hoerres, CEO, and Rebecca Critchley-Thorne, Ph.D., Director of Biomarker & Diagnostic Development, the company has developed technology and intellectual property based on a sys Read More
Definiens and Cernostics Partner to Develop Multiplexed Cancer Diagnostic Tests
Multi-color fluorescence slides analyzed by Definiens Tissue Studio to provide clinicians with more complete understanding of disease state Definiens, the number one Health Image Intelligence™ company, and Cernostics, a life sciences firm specializing in advanced cancer diagnostics, today announced a partnership to develop a unique multiplexed assay tool for the diagnosis of cancer. Read More
Pathology imaging firm Cernostics pulls in $2.6M
Slightly under-the-radar Cernostics Inc. has raised $2.6 million in equity, debt and options, according to a regulatory filing with the Securities and Exchange Commission. The newly rechristened Cernostics was previously known as Cernostics Pathology Inc., including in 2008 when it was spun off from Pittsburgh-based Cellumen Inc. At the time of the spinoff, Cernostics' aim was to focus on " Read More